MedPath

A randomized, open-label, single-dosing, 2x2 crossover study to compare the safety and pharmacokinetics of CKD-330 (fixed-dose combination of Candesartan Cilexetil 8 mg and Amlodipine 5 mg) with coadministration of the two separate drugs in healthy male volunteers (B)

Not Applicable
Completed
Conditions
Diseases of the circulatory system
Registration Number
KCT0001674
Lead Sponsor
Chungnam National University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Male
Target Recruitment
50
Inclusion Criteria

1. Healthy male volunteer in the age of 19-45
2. Body weight = 55 kg and in the range of calculated IBW(Ideal Body Weight) ±20%
3. Subject without a hereditary problems, chronic disease and morbid symptom
4. Suitable clinical laboratory test values
5. Subject who sign on an informed consent form willingly

Exclusion Criteria

1. Clinically significant disease with hepatobiliary, nephrological, neurologic, respiratory, haemato-oncological, endocrine, urogenital, psychiatric, musculoskeletal, immune, otorhinolaryngological, cardiovascular system
2. Gastrointestinal disease or gastrointestinal surgery
3. History of significant hypersensitivity reaction of amlodipine, candesartan, calcium channel blocker, angiotensin II receptor blocker or other drugs
4. Galactose intolerance
5. Sitting systolic blood pressure = 140 mmHg or< 90 mmHg, sitting diastolic blood pressure = 95 mmHg or < 60 mmHg, pulse = 100 beats per minute
6. Aspartate aminotransferase, Alanine aminotransferase, Total bilirubin > 2 x upper limit of normal range
7. Serum Creatinine > upper limit of normal range
8. Drug abuse
9. Subject treated metabolizing enzyme inducers or inhibitors within 1 month
10. Subject treated ethical the counter or herbal medicine within 2 weeks, over-the-counter or vitamin within 1 week
11. Subject treated Investigational product(include Bioequivalence test) within 3 months
12. Whole blood donation within 2 months, component blood donation or blood transfusion within 1 month
13. Continuously taking Alcohol > 21 units/week
14. Cigarette > 10 cigarettes/day
15. Subjects with planning of dental treatment or any surgery
16. Another clinical condition in judgement of investigator

Study & Design

Study Type
Interventional Study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
AUCt, Cmax of Candesartan and Amlodipine
Secondary Outcome Measures
NameTimeMethod
AUCinf, tmax, t1/2ß, CL/F of Candesartan and Amlodipine;Safety
© Copyright 2025. All Rights Reserved by MedPath